HSHarald Schennach

Harald Schennach

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Harald Schennach has a total of 124 co-authors. Here are the top co-authors by number of shared publications:

  • Anita Siller

    Central Institute for Blood Transfusion and Immunology, University Hospital of Innsbruck, Tirol Kliniken GmbH, Innsbruck, Austria

    13 shared publications
  • Peter Willeit

    Institute of Clinical Epidemiology, Public Health, Health Economics, Medical Statistics and Informatics, Medical University of Innsbruck, Innsbruck, Austria

    13 shared publications
  • Lena Tschiderer

    Institute of Clinical Epidemiology, Public Health, Health Economics, Medical Statistics and Informatics, Medical University of Innsbruck, Innsbruck, Austria

    10 shared publications
  • Lisa Seekircher

    Institute of Clinical Epidemiology, Public Health, Health Economics, Medical Statistics and Informatics, Medical University of Innsbruck, Innsbruck, Austria

    10 shared publications
  • Marco Amato

    Central Institute for Blood Transfusion and Immunology, University Hospital of Innsbruck, Tirol Kliniken GmbH, Innsbruck, Austria

    8 shared publications
  • Manfred Astl

    Central Institute for Blood Transfusion and Immunology, University Hospital Innsbruck, Tirol Kliniken GmbH, 6020 Innsbruck, Austria

    7 shared publications

Latest Publications

  • Open Access

    Adaptation of the Yield-Scaling Factor to Reduce Target Yield Deviation and Donation Time in Pathogen-Reduced Apheresis Platelet Collections Using the Sysmex XN1000 Blood Bank Mode

    by Marco Amato, Anita Siller, Lisa Seekircher, Manfred Astl, Lena Tschiderer, Peter Willeit, Harald Schennach

    Marco Amato, M.D., Anita Siller, Ph.D., Lisa Seekircher, Ph.D., Manfred Astl, Dipl.-Ing., Lena Tschiderer, Ph.D., Peter Willeit, M.D., Ph.D., and Harald Schennach, M.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2026.0075

  • Open Access

    Reorganization of Innate Immune Cell Lipid Profiles by Bioinspired Meroterpenoids to Limit Inflammation

    by Lorenz Waltl, David Holubek, Klaus Speck, Raphael Wildermuth, Franz‐Lucas Haut, Stephan Permann, Immanuel Plangger, Christian Steinborn, Zhigang Rao, Danilo D'AVino, et al.

    Lipidomics‐guided screening of unexplored natural product chemical space provides access to small molecules that globally reprogram cellular lipid profiles. Here, we show that the meroterpenoid cyclosmenospongine from Spongia sp . reshapes immune cell lipidomes, shifting them from pro‐inflammatory toward anti‐inflammatory and pro‐resolving mediators. Structural variation yielded derivatives that context‐dependently inhibit leukotriene biosynthesis to varying extents while upregulating pro‐resolving lipid mediators, epoxyeicosatrienoic acids, endocannabinoids, sphingosine‐1‐phosphate, and others in resting and activated innate immune cells in vitro, as well as in self‐resolving murine peritonitis and fibrosis in vivo. Mechanistically, meroterpenoids target 5‐lipoxygenase or 5‐lipoxygenase‐activating protein, promote 15‐lipoxygenase‐1 translocation to particulate sites, and inhibit monoacylglycerol lipase. They also redirect arachidonic acid from neutral lipids to specific phospholipids while increasing free arachidonic acid levels. Furthermore, meroterpenoids reprogram immune cell lipid metabolism by reducing neutral lipid, triacylglycerol, and cholesteryl ester levels, a shift that correlates with a lower capacity for leukotriene biosynthesis and is phenocopied by inhibiting sterol‐O‐acyltransferase, which catalyzes cholesterol esterification for storage, and diacylglycerol acyltransferase‐1/2, which catalyze the final step in triacylglycerol biosynthesis. In conclusion, specific meroterpenoids exert anti‐inflammatory effects by rewiring lipid mediator biosynthesis through structure‐controlled switches in lipid mediator classes, and an unexpected link between lipogenesis and inflammation.

  • Open Access

    Seroprevalence of IgM and IgG Antibodies Directed Against Hepatitis E Virus in 4867 Blood Donors From Tyrol, Austria

    by Lisa Seekircher, Annelies Mühlbacher, Lena Tschiderer, Marco Amato, Manfred Astl, Harald Schennach, Anita Siller, Peter Willeit

    There may be a risk of transmitting Hepatitis E Virus (HEV) through blood transfusions, however screening blood donors for HEV is not mandatory in Austria. We assessed the seroprevalence of anti–HEV antibodies among blood donors, thereby informing about the risk of HEV‐contaminated blood products. Between May and July 2022, we enrolled 4867 blood donors aged 18–70 years at 38 donation events spread across the Federal State of Tyrol, Austria. We measured anti–HEV IgG and IgM antibodies using five validated assays, based on which overall anti–HEV seropositivity was defined. We determined seroprevalences with 95% confidence intervals (CI) and calculated odds ratios for seropositivity using logistic regression. Median age of participants was 45.99 years (25th–75th percentile: 31.49–55.80); 41.15% were female, and 75.82% lived in rural areas. Anti–HEV IgM was detected in 13 individuals, i.e. 0.27% (95% CI: 0.16–0.47%). Anti–HEV IgG seroprevalence was 19.26% (18.17–20.40%) overall. It was higher in older blood donors – peaking in the 65–70–year age group (47.92%) –, higher in males (20.70%) than females (17.20%) and higher in urban (21.28%) compared to rural areas (18.61%). Multivariable adjusted odds ratios for IgG seropositivity were 1.19 for male sex (1.01–1.39; p = 0.033), 2.15 per 10–year older age (2.00–2.30; p < 0.001) and 1.21 for residing in an urban area (1.02–1.45; p = 0.030). Our findings indicate that HEV is widespread in Austria. Implementation of mandatory routine HEV nucleic acid testing should be considered in blood donations to enhance transfusion safety.

  • Virtual reality for pain and anxiety reduction during venous puncture procedures

    by Andreas Rosenecker, Marco Amato, Isabel Geiger, Simon Winkler, Peter Willeit, Harald Schennach, Anita Siller

    Venous puncture is a routine procedure in extracorporeal photopheresis (ECP) and may be associated with pain and anxiety. Virtual reality (VR) distraction has been shown to reduce distress in pediatric and acute settings. This study investigated if immersive VR can reduce pain and anxiety during venous puncture in ECP patients. A prospective, single-center clinical study with a within-subject crossover design was conducted at the University Hospital Innsbruck. A total of 21 adult patients underwent 2 consecutive ECP sessions, first with standard care and then with immersive VR distraction. Subjective pain and anxiety were assessed using numerical rating scales (NRS). The physiological parameters heart rate (HR), heart rate variability (HRV), respiratory rate (RR) and galvanic skin response were continuously monitored. The NRS pain scores were significantly lower with VR compared to standard care with a median of 1.00 (interquartile range, IQR 0.00-2.00) in both conditions (p = 0.031). Without vs. with VR, 23.8% vs. 4.8% of patients rated their pain > 2 during puncture. The NRS anxiety scores were not significantly reduced with a median of 0.00 (0.00-1.00) without VR vs. 0.00 (0.00-0.00) with VR (p = 0.066). Without vs. with VR, 23.8% vs. 14.3% of patients rated their anxiety > 1 during puncture and 48% of patients preferred VR for future treatment, while 38% preferred standard care. The findings support the feasibility and potential benefit of VR as a supportive, nonpharmacological intervention, regarding pain reduction. Larger trials in more diverse patient populations are warranted to confirm these results.

  • Open Access

    Babesiosis and Its Significance in Transfusion Medicine from a European Point of View

    by Marco Amato, Anita Siller, Harald Schennach

    Background: Babesiosis, caused by intraerythrocytic parasites of the genus Babesia, represents an emerging global health threat due to its capacity for persistent infection and transfusion transmission. The ability of Babesia spp. to establish chronic, asymptomatic infections lasting up to 2 years in immunocompetent hosts creates a substantial reservoir of infectious blood donors, making transfusion-transmitted babesiosis (TTB) a critical blood safety concern. Summary: The epidemiology of babesiosis differs markedly between regions, with B. microti predominating in North America and B. divergens in Europe. In the USA, seroprevalence studies among blood donors reveal rates of 0.38% in endemic regions. In 2019, the US Food and Drug Administration (FDA) issued nonbinding recommendations for year-round regional nucleic acid testing of individual donations in 14 endemic states and Washington DC, or alternatively, the use of FDA-approved pathogen reduction technology for blood components [Pathogens. 2021;10(9):1176; Recommendations for reducing the risk of transfusion-transmitted babesiosis, 2019]. TTB can result in severe clinical complications with mortality rates approaching 20%, particularly affecting immunocompromised recipients. European studies demonstrate significantly lower prevalence rates, with minimal Babesia DNA detection in blood donor populations from Austria [Transfus Med Hemother. 2023;50(4):330–3] and Poland [Przegl Epidemiol. 2023;77(2):146–52], despite serological evidence of exposure. Current detection methods include microscopic examination, nucleic acid amplification, antigen detection, and antibody testing, with screening programs proving effective in endemic regions. Key Messages: Persistent Babesia infections pose a significant threat to blood safety, necessitating region-specific risk assessment and mitigation strategies. The substantial difference in prevalence between North American and European blood donor populations highlights the importance of tailored approaches to screening implementation. Enhanced surveillance, novel therapeutic strategies, and comprehensive prevention measures – including advanced diagnostics, tick-avoidance programs, and pathogen reduction technologies – are essential for minimizing the global health burden of persistent babesiosis and protecting vulnerable populations from this emerging transfusion-transmitted threat.


  • Open Access

    Francisella tularensis surveillance—infection-induced seroprevalences in Western Austria 2025

    by Anita Siller, Lidia Chitimia-Dobler, Fabian Wilhelm, Marco Amato, Johannes P Borde, Janne Cadamuro, Harald Schennach, Peter Fraunberger, Peter Willeit, Gerhard Dobler, et al.


  • Optimizing Buffy Coat Pooling: Enhancing Platelet Yield Through Platelet Count-Based Sorting

    by Marco Amato, Manfred Astl, Lisa Seekircher, Lena Tschiderer, Peter Willeit, Harald Schennach, Anita Siller

  • Open Access

    Optimized Protocol for Producing Pathogen-Inactivated Double-Dose Platelet Concentrates From Six Pooled Buffy Coats

    by Marco Amato, Lisa Seekircher, Lena Tschiderer, Peter Willeit, Harald Schennach, Anita Siller

    Pooled platelet (PLT) production methods differ worldwide. In Europe, the buffy coat (BC) method is predominantly used, with four to eight BCs being pooled to produce single- or double-dose PLT products. The European Directorate for the Quality of Medicines & HealthCare (EDQM) blood guide and Austrian legislation define a therapeutic PLT unit as ≥ 2 × 1011 PLTs/unit. We optimized the manufacturing steps to produce doubledose PLT products from six BCs, aiming to enhance production efficiency while maintaining product quality. We stepwise optimized our protocol starting from five BCs (BC5) (N=107). First, we included an additional BC (BC6) (N=110). Second, we used a hematology analyzer (Sysmex XN-1000) equipped with blood bank mode, which is a novel software application for measuring PLT counts in PLT units (BC6+XN-1000) (N=106). Third, we optimized the blood cell separator (BCS) settings to produce higher-volume BCs (BC6+XN-1000+BCS) (N=107). Fourth, we adapted the centrifugation (BC6+XN-1000+BCS+CF) (N=197). All units were pathogen-inactivated using the INTERCEPT blood system (amotosalen/ultraviolet A). Each optimization step significantly increased the yield ( × 1011/PLT concentrate) (P P <0.001). After stepwise protocol optimization, we could produce pathogen-inactivated double-dose PLT concentrates by pooling six BCs, complying with national regulations and EDQM quality requirements while reducing costs and minimizing blood wastage.


  • Open Access

    XN-1000 Hematology Analyzer as an Alternative to Flow Cytometry for Measuring Residual Cells in Blood Components

    by Anita Siller, Lisa Seekircher, Daniela Schmidt, Lena Tschiderer, Peter Willeit, Harald Schennach, Marco Amato

    Anita Siller , Ph.D., Lisa Seekircher , Ph.D., Daniela Schmidt , Lena Tschiderer , Ph.D., Peter Willeit , Ph.D., Harald Schennach , M.D., and Marco Amato , M.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2024.0448


  • Open Access

    Anti-HBs Seroprevalence in Blood Donors from Tyrol, Austria

    by Lisa Seekircher, Annelies Mühlbacher, Lena Tschiderer, Gregor A. Wachter, Manfred Astl, Harald Schennach, Anita Siller, Peter Willeit

    Background/Objectives: Antibodies against the hepatitis B surface antigen (anti-HBs) are a marker of immunity against hepatitis B virus (HBV) infections. There is uncertainty about the anti-HBs seroprevalence in the general population of Austria. Methods: We conducted a cross-sectional analysis in blood donors from the Federal State of Tyrol in Austria (August–September 2023) to estimate anti-HBs seroprevalence and median antibody levels. Results: We enrolled 3935 blood donors (median age 47.6 years [25th–75th percentile: 33.3–56.6]; 40.7% female), who were hepatitis B surface antigen negative and had no detectable HBV-DNA. Overall seroprevalence was 51.4% (95% CI: 49.8–52.9%). Anti-HBs seropositivity decreased with higher age (p < 0.001), with 70.3% (66.1–74.3%) being seropositive among participants < 25 years of age and 30.2% (24.2–36.9%) in those aged ≥ 65 years. More females than males were seropositive (54.3% [51.8–56.7%] vs. 49.4% [47.4–51.4%]; p = 0.003). Seroprevalence was significantly higher in urban than in rural areas in participants aged 40 to p = 0.045) and ≥55 years (p = 0.001). Among 2022 seropositive participants, the overall median anti-HBs antibody level was 539.3 IU/L (25th–75th percentile: 116.3–5417.0). Furthermore, 5% of the participants had an anti-HBs antibody level between 10 and <20 IU/L, 18% between 20 and <100 IU/L, and 77% ≥100 IU/L. Conclusions: Anti-HBs seroprevalence in blood donors from Tyrol, Austria, was 51.4% between August and September 2023 and differed across age, sex, and residence area. Catch-up vaccination programs, especially targeting the elderly living in rural areas, are needed to close HBV immunity gaps.